ALLK Jan 2024 10.000 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 10.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
GlobeNewswireAllakos Provides Business Update and Reports Third Quarter 2023 Financial Results
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2023. Recent Allakos Events Completed enrollment in both the Phase 2 study of subcutaneous lirentelimab in patients with atopic dermatitis and the Phase 2b study of subcutaneous
Simply Wall St.Following a 63% decline over last year, recent gains may please Allakos Inc. (NASDAQ:ALLK) institutional owners
Key Insights Given the large stake in the stock by institutions, Allakos' stock price might be vulnerable to their...
Motley FoolWhy Shares of Allakos Are Up Wednesday
Shares of clinical-stage biotech company Allakos (NASDAQ: ALLK) were up more than 15% as of 11:40 a.m. on Wednesday. Despite the rise, Allakos' stock is still down more than 70% so far this year. Allakos focuses on monoclonal antibodies to trigger responses in the body's immune cells to treat various conditions, including allergies, and inflammatory and proliferative diseases.
